Vertex Pharmaceuticals Incorporated
$538.82
+9.13 · +1.72% today
Market open · updated 12:44:26 PM ET
- High
- $534.62 11:05 AM
- Low
- $505.01 4:25 AM
Against the S&P 500 Price change through Oct 27, 2026
VRTX+14.93%
S&P 500+12.87%
VRTX+24.00%
S&P 500+12.32%
VRTX+46.65%
S&P 500+87.41%
VRTX+187.96%
S&P 500+69.55%
Key numbers
- Previous close
- $529.69
- Open
- $536.46
- Day's range
- $534.02 – $546.60
- 52-week range
- $403.16 – $560.25
- Volume
- 441,474
- Average volume
- 1.4 million
- Market value
- $136.6 billion
- Price to earnings
- 29.9last 12 months
- Earnings per share
- $17.35last 12 months
- Beta
- 0.32moves less than the market
- Dividend
- None
- 50-day average
- $523.08
- 200-day average
- $478.24
Monday, Nov 2, 2026, after the close.
Analyst price targets and the full financials are in the terminal.
Who Vertex Pharmaceuticals competes with From our value chain
Vertex Pharmaceuticals in the news
No desk stories on VRTX yet. When we write about it, the story leads this list.
- HeadlineAhead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research · October 28, 2026 at 10:16 AM ET
- HeadlineVertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's WhyZacks Investment Research · October 26, 2026 at 6:50 PM ET
- HeadlineVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · October 26, 2026 at 11:01 AM ET
- HeadlineVertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 TranscriptSeeking Alpha · October 24, 2026 at 3:27 AM ET
- HeadlinePhase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026Business Wire · October 23, 2026 at 1:42 PM ET
- HeadlineVertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research · October 20, 2026 at 6:51 PM ET
- HeadlineVertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key FactsZacks Investment Research · October 15, 2026 at 7:00 PM ET
- CongressRo Khanna bought $1,001 - $15,000 of VRTXHouse filing · disclosed Oct 9, 2026
Earnings
Next report: Monday, Nov 2, 2026, after the close.
Congress trades in VRTX
4 purchases and 4 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 4, 2026 | Oct 9, 2026 |
| David TaylorHouse · R-Ohio | Sale | $1,001 - $15,000 | Aug 26, 2026 | Sep 7, 2026 |
| Alan ArmstrongSenate · R-Oklahoma | Purchase | $1,001 - $15,000 | Mar 27, 2026 | Jul 22, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Apr 13, 2026 | May 13, 2026 |
| David TaylorHouse · R-Ohio | Sale | $1,001 - $15,000 | Jan 29, 2026 | Feb 3, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 29, 2025 | Oct 3, 2025 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Sep 5, 2025 | Oct 3, 2025 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Aug 26, 2025 | Sep 12, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,400
- Headquarters
- Boston, Massachusetts
- Website
- vrtx.com
- Listed
- Jul 24, 1991
More biotechnology stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.